NEW YORK (GenomeWeb News) – Orchid Cellmark plans to shut down its paternity testing operations in East Lansing, Mich., and move them to its facilities in Dayton, Ohio, the company said today.

The DNA testing firm plans to bring all of its US paternity operations "under one roof" in an effort to increase efficiency, Orchid CEO Thomas Bologna said in a statement today. The Dayton facility already houses some paternity testing services, and the company's call center and customer operations are based in Dayton as well, Bologna said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.